UNSPSC 51102826: Ciprofloxacin/dextrose

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.

UNSPSC 51102826 Ciprofloxacin/dextrose is a Commodity code that in recent state and local procurement shows minimal direct purchasing activity under this specific pharmaceutical product code. The recent opportunities tagged to this code instead reflect broader pharmaceutical procurement—generic multi-source drugs, naloxone and drug deactivation systems, and medical first aid supplies—rather than ciprofloxacin/dextrose specifically. State and local health departments, fire departments, and cooperative purchasing alliances are the primary issuing bodies, with solicitations ranging from formal RFPs for statewide pharmaceutical contracts to IFBs for emergency medical supplies.

Recent activity concentrates in Florida, Texas, and Minnesota. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and coverage extending to Oregon; the RFP requires vendors to supply through three authorized wholesalers and mandates cGMP and DSCSA certification, with pricing weighted at 75 percent of evaluation. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, and the City of Tampa's March 25, 2026 IFB 26-P-00145 for medical and first aid supplies to the Fire Department Rescue Division, designated as sheltered for certified Small Local Business Enterprises with a 5 percent bid discount and an estimated contract value of $700,000.00. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 for direct-to-manufacturer prescription capabilities as a market intelligence tool to inform future pharmacy benefit procurement strategy.